Get the Stockscreener App
20.45
4.87%
0.95
Pre-market:
20.81
0.36
+1.76%
Dianthus Therapeutics Inc stock is traded at $20.45, with a volume of 429.59K.
It is up +4.87% in the last 24 hours and up +4.93% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$19.50
Open:
$19.17
24h Volume:
429.59K
Relative Volume:
1.34
Market Cap:
$601.08M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.6894
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
+9.30%
1M Performance:
+4.93%
6M Performance:
-27.94%
1Y Performance:
-12.04%
1-Day Range:
$18.65
$21.40
1-Week Range:
$18.37
$21.40
52-Week Range:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.45 | 601.08M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Fmr LLC Purchases 36,133 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Walleye Capital LLC Buys 52,890 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Vanguard Group Inc. Sells 20,331 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Wellington Management Group LLP Boosts Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Corebridge Financial Inc. - Defense World
ADAR1 Capital Management LLC Has $385,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Alliancebernstein L.P. - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by American Century Companies Inc. - Defense World
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33 - MarketBeat
Rhenman & Partners Asset Management AB Sells 36,000 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? - MSN
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month LowShould You Sell? - MarketBeat
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7%Here's What Happened - MarketBeat
DNTH Stock Touches 52-Week Low at $16.32 Amid Market Challenges - Investing.com UK
Swiss National Bank Sells 2,900 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Trading 6.5% HigherStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week LowWhat's Next? - MarketBeat
Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Deep Track Capital, LP Acquires Significant Stake in Dianthus Th - GuruFocus
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's What Happened - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus
Cantor Fitzgerald Issues Positive Estimate for DNTH Earnings - MarketBeat
HC Wainwright Brokers Raise Earnings Estimates for DNTH - MarketBeat
FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat
Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat
FY2025 EPS Estimates for DNTH Raised by Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
HC Wainwright Issues Optimistic Outlook for DNTH Earnings - Defense World
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):